Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division. The patent includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems for expressing the human Klotho protein. This intellectual property milestone supports the development of Greenland Mines’ KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders.
The patent strengthens the company’s Klotho-based therapeutic platform, which is central to its biotech division’s pipeline. KLTO-202 is the primary indication for ALS, a progressive neurodegenerative disease with limited treatment options. By securing patent protection in Australia, Greenland Mines can advance clinical development and potential commercialization in that jurisdiction. The company also plans to pursue patent protection in other key markets.
Greenland Mines is a dual-division company with mining operations focused on rare earth materials in Greenland and a biotech division developing gene therapies. The patent news comes as the company progresses its KLTO-202 program, which aims to leverage the Klotho protein’s neuroprotective properties. Klotho is known for its role in aging and neuronal health, and its expression via gene therapy could slow or halt disease progression in ALS patients.
"This patent issuance is a critical step in protecting our innovative gene therapy platform," said a company spokesperson. "It validates our approach to treating neuromuscular diseases and strengthens our position as we advance KLTO-202 toward clinical trials." The company’s strategy includes building a multi-asset platform with exposure to rare earth magnet materials and precious metals while advancing its biotech pipeline.
The full press release is available at https://nnw.fm/PVbbH. For more information about Greenland Mines and its latest updates, visit the company’s newsroom at https://ibn.fm/GRML.
This development underscores the growing importance of intellectual property in the gene therapy space. As companies race to develop treatments for neurodegenerative diseases, patent protection can provide a competitive edge and attract investment. Greenland Mines’ ability to secure patents in multiple jurisdictions may enhance the value of its biotech division and support its broader corporate strategy.
